Anderson RJ, Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
Vaccine 2007;
25 Suppl 2:B24-34. [PMID:
17698262 DOI:
10.1016/j.vaccine.2007.05.030]
[Citation(s) in RCA: 66] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2007] [Revised: 05/06/2007] [Accepted: 05/15/2007] [Indexed: 12/14/2022]
Abstract
Plasmid DNA and viral vector-based cancer vaccines have many inherent features that make them promising cancer vaccine candidates. This review focuses on the use of plasmid DNA and viral vector vaccines to deliver tumour-specific antigens to induce a tumour-specific immune response. Examples of different antigen delivery systems that have been tested in recent clinical trials are summarised and advantages and disadvantages of a number of delivery systems and approaches are discussed. Finally, an outlook on how plasmid DNA and viral vectors might be developed further as cancer vaccines is provided.
Collapse